Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OCULUS INC.OVTZ · Entity 8451 | Director | July 21, 2023 | July 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OCULUS INC.
Report date July 21, 2023 · Filed July 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2023-07-21 | Direct | 0 |
Reported balance
After 2020-07-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-21 · Disposition to issuer · Disposed 210,000 · Balance 0 F1: The exercise price reported above was converted from the Canadian exercise price of C$0.35 using an exchange rate of C$1.34460=US$1.00 F2: Options were granted on July 21, 2020 and vested as follows: 20% on January 21, 2021, 20% on July 21, 2021, 20% on January 21, 2022, 20% on July 21, 2022 and 20% on January 21, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price reported above was converted from the Canadian exercise price of C$0.35 using an exchange rate of C$1.34460=US$1.00
F2: Options were granted on July 21, 2020 and vested as follows: 20% on January 21, 2021, 20% on July 21, 2021, 20% on January 21, 2022, 20% on July 21, 2022 and 20% on January 21, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2020 Filed Sep 3, 2020 21:20 UTC | OCULUS INC. OVTZ · Entity 8451 | GrantStock Options · Derivative | 210,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001437749-20-019319 · rdgdoc.xml · derivative · entry 1 LOVERSO MAURICE · CIK 0001232358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common stock · 210,000 shares Expires 2023-07-21 F1 · derivative.exercise_price: The exercise price reported above was converted from the Canadian exercise price of C$0.35 using an exchange rate of C$1.34460=US$1.00 F2 · derivative.exercise_date: Options were granted on July 21, 2020 and vest as follows: 20% on January 21, 2021, 20% on July 21, 2021, 20% on January 21, 2022, 20% on July 21, 2022 and 20% on January 21, 2023. Read SEC document |
| July 21, 2020 Filed Jul 21, 2023 19:07 UTC | OCULUS INC. OVTZ · Entity 8451 | Disposition to issuerStock Options · Derivative | 210,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001437749-23-020431 · rdgdoc.xml · derivative · entry 1 LOVERSO MAURICE · CIK 0001232358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 210,000 shares Expires 2023-07-21 F1 · derivative.exercise_price: The exercise price reported above was converted from the Canadian exercise price of C$0.35 using an exchange rate of C$1.34460=US$1.00 F2 · derivative.exercise_date: Options were granted on July 21, 2020 and vested as follows: 20% on January 21, 2021, 20% on July 21, 2021, 20% on January 21, 2022, 20% on July 21, 2022 and 20% on January 21, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.